A Study of BGM-2121 in Patients With Advanced Solid Tumors
Phase 1 – testing safety in a small group of people
Conditions:
Advanced Solid Tumors
Sponsor: BioGate Precision Medicine Corp.
trial.available_in:
БГ
Overview
This study is to explore the safety, tolerability, pharmacokinetics, and preliminary efficacy of BGM-2121 in adult patients with advanced solid tumors.
Who can participate
Inclusion Criteria:
1. With either gender aged ≥ 18 years,
2. Has a confirmed diagnosis of advanced solid tumor(s),
3. The subject has received and failed standard-of-care anti-cancer therapy
4. Has at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST)
5. ...
Exclusion Criteria:
1. Has any ongoing toxicity from previous anti-cancer treatments
2. Has signs or symptoms of end-stage organ failure, major chronic illnesses other than cancer(s)
3. History of another primary malignancy within the last three years
4. ...
БГ